Johnson & Johnson vaccine manufacturing partner Catalent scores approval for Indiana plant: reports

URLhttps://www.fiercepharma.com/manufacturing/catalen
SourceFIERCE Pharma
Date Published03/23/2021
Author NameFraiser Kansteiner
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Johnson & Johnson
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:Outsourced
City reshored to:Bloomington
State(s) reshored to:IN
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredfill-finish J&J single-dose Covid-19 vaccine
What domestic positive factors made reshoring more attractive?Lead time/Time to market, Skilled workforce availability/training, Under-utilized capacity, Other, Covid-19, import replacement
Find Reshoring Articles